Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes

Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom China New York New Jersey Austria California

In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration.In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving six weeks of GZR4 treatment were safe and well tolerated. GZR4 also exhibited improvements in fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and time in range (TIR) across all dosage groups, outperforming the insulin degludec (IDeg) group.(Media)
[e-mail] (Business Development)
[e-mail] (Medical Information)

Logo - https://mma.prnewswire.com/media/2439708/Gan_Lee_Pharmaceuticals_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin-gzr4-at-the-60th-annual-meeting-of-the-european-association-for-the-study-of-diabetes-easd-2024-302248338.html